The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Bendamustine 100 mg Powder for Concentrate for Solution for Infusion



Teva B.V.PA1986/121/002

Main Information

Trade NameBendamustine 100 mg Powder for Concentrate for Solution for Infusion
Active SubstancesBendamustine hydrochloride
Dosage FormPowder for concentrate for solution for infusion
Licence HolderTeva B.V.
Licence NumberPA1986/121/002

Group Information

ATC CodeL01AA Nitrogen mustard analogues
L01AA09 bendamustine

Status

License statusAuthorised
Licence Issued15/05/2015
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back